126337-04-0

Upstream product

• 51660-08-3 4-Chloro-6-oxo-3-phenyl-1,6-dihydropyridazine 
• 72857-86-4 α,β-dibromo-γ-phenylcrotonolactone 
• 90766-97-5 5-bromo-6-phenylpyridazin-3(2H)-one 
• 51660-08-3 5-Chloro-3-hydroxy-6-phenylpyridazine 

Downstream Products

• 126337-06-2 5-azido-2-methyl-6-phenylpyridazin-3(2H)-one 
• 1610354-61-4 5-amino-6-phenyl-2-(2,2,2-trifluoroethyl)pyridazin-3(2H)-one 
• 1610354-27-2 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(6-oxo-3-phenyl-1-(2,2,2-trifluoroethyl)-1,6-dihydropyridazin-4-yl)urea 
• 1610354-60-3 5-azido-6-phenyl-2-(2,2,2-trifluoroethyl)pyridazin-3(2H)-one 
• 126337-05-1 4-Azido-6-chloro-3-phenylpyridazine 
• 126337-08-4 C₂₈H₂₂N₃OP 
• 126337-07-3 C₂₈H₂₁ClN₃P 
• 126336-93-4 5-Acetylamino-3-chloro-6-phenylpyridazine 
• 79852-16-7 5-Amino-3-chloro-6-phenylpyridazine 
• 87769-63-9 5-amino-6-phenyl-1,6-dihydropyridazin-3(2H)-one 

Relevant academic research and scientific papers

Ureido-Pyridazinone Derivatives: Insights into the Structural and Conformational Properties for STAT3 Inhibition

Three new ureido-pyridazinone derivatives, which are structurally related to the known STAT3 inhibitor AVS-0288, were designed by taking into account the structure-activity relationships determined for several ureido-oxadiazole derivatives previously studied by our group. Their synthesis was first attempted through suitable 5-aminopyridazinone intermediates (6a and 6b), which molecular structures were confirmed by means of X-ray diffraction data on 6a. Amine functionalization was unsuccessful, therefore, an alternative method was devised. Dual-luciferase and AlphaScreen-based assays were used to test their activity. The obtained data were rationalized on the basis of a modeling study, which focused our attention on the geometrical preferences of the ureido moiety. Computational results seem to indicate that both the 1,2,5-oxadiazole ring and the extended ZZ arrangement are essential and probably act in a synergistic way to confer significant activity against STAT3.

PYRROLIDINYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS

Compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts, or solvates or prodrugs thereof, where R1, R2, Ra, Rb, Rc, Rd, X, Ring B, and Ring C are as defined herein, and wherein Ring B moiety and the NH-C(=X)-NH moiety are in the trans configuration, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis and pelvic pain syndrome.

Pyridazines. Part XXIX: Synthesis and platelet aggregation inhibition activity of 5-substituted-6-phenyl-3(2H)-pyridazinones. Novel aspects of their biological actions

A series of 6-phenyl-3(2H)-pyridazinones with a diverse range of substituents in the 5-position have been prepared and evaluated in the search for new antiplatelet agents. A significant dependence of the substituent on the inhibitory effect has been observed. The pharmacological study of these compounds confirms that modification of the chemical group at position 5 of the 6-phenyl-3(2H)-pyridazinone system influences both variations in the antiplatelet activity and the mechanism of action.

Ring Closure of 4-Azido-3-phenyl-pyridazines to Pyridazinoindoles

The cyclization of 4-azido-3-phenylpyridazines and 7-azido-6-phenyltetrazolopyridazine by heating with strong acids like methanesulfonic acid affords 5H-pyridazinoindoles or 10H-tetrazolopyridazinoindoles, respectively, whe

Synthesis of Aminopyridazines from Azidopyridazines and Tetrazolopyridazines

Azidopyridazines 3, 4, 24 and tetrazolopyridazines 10, 13, 28 can be converted to the corresponding aminopyridazines, by reaction with triphenylphosphine via phosphazenes and subsequent hydrolysis (Staudinger reaction).